Literature DB >> 2033665

Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

C M Drysdale1, G N Pavlakis.   

Abstract

The mechanism of induction of gene expression of the human immunodeficiency virus type 1 long terminal repeat (LTR) by the Tat transactivator protein was studied in a cell fusion assay. Tat causes a rapid activation of both transcription from the LTR and accumulation of hybrid LTR-chloramphenicol acetyltransferase mRNAs. Approximately 4 h after induction by Tat, expression from the LTR promoter is down-regulated, resulting in a decrease in the accumulation of LTR mRNA. This down-regulation of expression occurs in the continued presence of Tat. Protein synthesis inhibitors can block this down-regulation; therefore, the postinduction repression of expression is dependent upon de novo protein synthesis. We propose that a labile cellular protein(s) is responsible for the low levels of human immunodeficiency virus type 1 expression, possibly contributing to the establishment of a latent state of viral expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033665      PMCID: PMC240959     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat.

Authors:  J Hauber; B R Cullen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

3.  A quantitative bioassay for HIV-1 based on trans-activation.

Authors:  B K Felber; G N Pavlakis
Journal:  Science       Date:  1988-01-08       Impact factor: 47.728

Review 4.  Regulation of inducible and tissue-specific gene expression.

Authors:  T Maniatis; S Goodbourn; J A Fischer
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

Review 5.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

6.  Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1.

Authors:  M R Sadaie; T Benter; F Wong-Staal
Journal:  Science       Date:  1988-02-19       Impact factor: 47.728

Review 7.  Regulation of expression of the c-myc proto-oncogene.

Authors:  K B Marcu
Journal:  Bioessays       Date:  1987-01       Impact factor: 4.345

8.  Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events.

Authors:  J Hauber; A Perkins; E P Heimer; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

9.  Transcriptional but not translational regulation of HIV-1 by the tat gene product.

Authors:  A P Rice; M B Mathews
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

10.  In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.

Authors:  H Dinter; R Chiu; M Imagawa; M Karin; K A Jones
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  8 in total

1.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.

Authors:  S Schwartz; M Campbell; G Nasioulas; J Harrison; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Identification of novel import and export signals of human TAP, the protein that binds to the constitutive transport element of the type D retrovirus mRNAs.

Authors:  J Bear; W Tan; A S Zolotukhin; C Tabernero; E A Hudson; B K Felber
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.

Authors:  F Demarchi; F d'Adda di Fagagna; A Falaschi; M Giacca
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons.

Authors:  T Dragic; P Charneau; F Clavel; M Alizon
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells.

Authors:  S C Flores; J C Marecki; K P Harper; S K Bose; S K Nelson; J M McCord
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.

Authors:  M C Hsu; U Dhingra; J V Earley; M Holly; D Keith; C M Nalin; A R Richou; A D Schutt; S Y Tam; M J Potash
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

8.  Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression.

Authors:  M Tremblay; S Meloche; S Gratton; M A Wainberg; R P Sékaly
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.